Enterprise AI Analysis
Explainable artificial intelligence for brain tumor classification via fine-tuned transfer learning
This study proposes an efficient and interpretable deep learning (DL) model for brain tumor classification, utilizing transfer learning with the ResNet50 architecture. The model is trained to distinguish among three tumor types (glioma, meningioma, and pituitary tumors) and normal brain MRI scans. It uses fine-tuned ResNet50 with extensive data augmentation to mitigate overfitting on limited medical datasets. The model achieved 99.41% accuracy and integrates SHAP for interpretability, visualizing feature importance at the pixel level. This system provides transparent and trustworthy predictions to support radiologists and healthcare professionals in early diagnosis.
Executive Impact & Key Findings
Our advanced AI model achieves market-leading performance in brain tumor classification, delivering actionable insights with unparalleled accuracy and reliability.
0
Overall Accuracy
0
Precision
0
Sensitivity
0
F1-Score
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Our AI-Driven Approach
Our approach leverages transfer learning with a fine-tuned ResNet50 architecture, combining it with extensive data augmentation. Key steps include preprocessing (noise reduction, intensity normalization, brain extraction), data augmentation (rotation, flipping, scaling), feature extraction via ResNet50, classification with a softmax layer, and decision-making. Interpretability is provided by SHAP. The model was trained on 3,264 MRI scans from the BT-large-4c dataset, split into 75% training, 15% validation, and 10% testing. Adam optimizer with a learning rate of 0.00001 and a batch size of 64 was used over 100 epochs, incorporating early stopping to prevent overfitting.
Unparalleled Classification Performance
The proposed model achieved outstanding performance on the test dataset: 99.41% accuracy, 99.15% precision, 99.09% sensitivity, 98.18% specificity, and a 98.91% F1-score. These metrics confirm the model's ability to accurately differentiate between glioma, meningioma, and pituitary tumor classes. The low disparity between training and validation accuracy further indicates strong generalization capability. Comparative analysis against VGG16, MobileNet, and DenseNet201 showed superior performance across all evaluation metrics. An ablation study highlighted the critical role of ImageNet pre-training, fine-tuning, and aggressive data augmentation in achieving optimal performance.
Transparent AI for Clinical Trust
SHAP (Shapley Additive Explanations) was integrated to provide pixel-level interpretability, visualizing feature importance. SHAP heatmaps highlight red regions for positive contributions to a prediction and blue for suppressive features, demonstrating that the model focuses on medically relevant tumor regions. This enhances transparency and clinician trust, enabling better understanding and validation of classification outcomes. The pituitary tumor class exhibited the highest mean SHAP score (0.00145) with activations in sellar and suprasellar zones, aligning with clinical patterns.
99.41%
Overall Accuracy Achieved for Brain Tumor Classification
Enterprise Process Flow
MRI Input Images
→
Preprocessing
→
Data Augmentation
→
Feature Extraction (ResNet50)
→
Classification
→
Explainability (SHAP)
| Model | Accuracy | Precision | Sensitivity | Specificity | F1-Score |
|---|---|---|---|---|---|
| VGG16 [53] | 0.94 | 0.93 | 0.92 | 0.95 | 0.92 |
| MobileNet [54] | 0.95 | 0.94 | 0.94 | 0.96 | 0.94 |
| DenseNet201 [55] | 0.96 | 0.95 | 0.95 | 0.97 | 0.95 |
| Proposed Model | 0.9941 | 0.9915 | 0.9909 | 0.9818 | 0.9891 |
|
|||||
Real-World Impact & Clinical Trust
The integration of SHAP-based explainability ensures that the model's predictions are not black-box, providing vital insights into its decision-making process. This transparency fosters greater clinical trust, allowing radiologists and healthcare professionals to validate AI-assisted diagnoses and integrate them confidently into routine clinical practice. By aligning model attention with medically relevant tumor regions, our system supports more informed decision-making and potentially earlier intervention for brain tumor patients. This leads to improved treatment outcomes and reduced patient mortality rates.
Calculate Your Potential ROI
Discover the tangible benefits of integrating explainable AI into your operations. Estimate your annual savings and reclaimed productivity.
Your AI Implementation Roadmap
A phased approach to integrate cutting-edge AI solutions seamlessly into your enterprise workflow.
Phase 01: Discovery & Strategy
In-depth analysis of current workflows, identification of key AI opportunities, and tailored strategy development. Establish clear objectives and success metrics.
Phase 02: Model Development & Customization
Building or fine-tuning AI models like ResNet50 with explainability (SHAP), data preparation, and initial prototyping using your specific datasets.
Phase 03: Integration & Validation
Seamless integration of the AI model into existing systems, rigorous testing, validation against real-world data, and performance optimization.
Phase 04: Deployment & Monitoring
Full-scale deployment, continuous monitoring of model performance, and iterative refinement to ensure sustained value and adaptability.
Ready to Transform Your Enterprise with AI?
Book a free 30-minute consultation with our AI specialists to discuss your unique needs and how our solutions can drive your success.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat